Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency
Murielle Surquin, Christian Tielemans, Joëlle Nortier, Michel Jadoul, Patrick Peeters, Miroslav Ryba, Ludek Roznovsky, József Domán, Xavier Barthelemy, Priya Diana Crasta, Marc Messier, Sophie Houard
DOI: 10.4161/hv.7.9.16225
Klíčová slova: Adjuvants, Immunologic, Aged, Aged, 80 and over, Drug Combinations, Female, Follow-Up Studies, Hepatitis B, Hepatitis B Antibodies, Hepatitis B Vaccines, Humans, Internationality, Lipid A, Male, Middle Aged, Primary Prevention, Renal Insufficiency, Saponins, Therapies, Investigational, Vaccination
Anotace: BACKGROUND: Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination. BACKGROUND: Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination. BACKGROUND: Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination. BACKGROUND: Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection and higher anti-HBs antibody concentrations in patients with renal insufficiency than four doses of FENDrix™ (HB-AS04), an adjuvanted HBV vaccine licensed in Europe for use in this population. This study evaluated persistence of immune response up to 36 months after primary vaccination.
Citace: SURQUIN, Murielle, Christian TIELEMANS, Joëlle NORTIER, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Human vaccines. 2011, 7(9), 913-918. ISSN 15548619. Dostupné z: doi:10.4161/hv.7.9.16225